| Combination of | |
|---|---|
| Calcium acetate | Mineral supplement |
| Magnesium carbonate | Mineral supplement |
| Clinical data | |
| Pregnancy cat. | n/a |
| Legal status | Rx Prescription only |
| Routes | Oral |
| Identifiers | |
| CAS number | 62-54-4 546-93-0 |
| ATC code | V03AE04 |
| PubChem | CID 11029 |
| (what is this?) (verify) |
|
Calcium acetate/magnesium carbonate is a fixed-dose combination drug that contains 110 mg calcium and 60 mg magnesium indicated as a phosphate binder for dialysis patients suffering from hyperphosphataemia (abnormal high serum phosphorus levels).[1] It is registered by Fresenius Medical Care under the trade names Renepho (Belgium) and OsvaRen (other EMEA).
Contents |
Phosphorus is contained in food with high protein content as well as in processed food. It is absorbed by the gut. Healthy kidneys remove excess phosphorus from the body. One of the consequences of renal failure is inadequate removal of phosphorus resulting in increased serum phosphorus levels. This may worsen the overproduction of parathyroid hormone (hyperparathyroidism), may lead to calcification of blood vessels and is associated with cardiovascular mortality.[2] In addition to dialysis therapy and dietary restrictions, a pharmaceutical therapy to lower serum phosphorus levels is recommended.[3]
Calcium acetate/magnesium carbonate is taken orally together with the meal.[1] Calcium acetate and magnesium carbonate compounds bind phosphorus derived from food thereby forming indigestible phosphate salts in the intestine that are subsequently excreted with the faeces. The aim of the therapy is to reach a normal serum phosphorus level, i.e. between 0.81 - 1.45 mmol/l (2.5 - 4.5 mg/dl).[2]
Side effects from pharmaceutical therapy such as gastrointestinal disorders, e.g. nausea, constipation or diarrhoea may occur, as well as metabolism and nutritional disorders, e.g. hypercalcaemia or hypermagnesaemia.[1]